Blood

Vol. 146, Issue Supplement 2 Issue Supplement 2 2025
6
Articles

Articles in this Issue

Whole genome transcriptome sequencing in inherited bone marrow failure syndromes and related diseases – the ibmdx study

Lucy Fox, William Stevenson, Graham Lieschke et al. Nov 24, 2025 pp. LBA-4-LBA-4 10.1182/blood-2025-lba-4

Abstract Inherited bone marrow failure syndromes (IBMFS) are a group of monogenic diseases of diverse pathogenesis manifesting as single or...

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

Simon Harrison, Phoebe Joy Ho, Sueh-Li Lim et al. Nov 24, 2025 pp. LBA-1-LBA-1 10.1182/blood-2025-lba-1

Abstract Introduction: KLN-1010 is an investigational gene therapy administered intravenously to generate a novel, fully human anti-BCMA CAR...

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Hanny Al-Samkari, Adam Cuker, Francesco Zaja et al. Nov 24, 2025 pp. LBA-2-LBA-2 10.1182/blood-2025-lba-2

Abstract Introduction: B cells and the B-cell activating factor (BAFF) pathway are key in immune thrombocytopenia (ITP) pathophysiology. Ian...

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

María-Victoria Mateos, Nizar Bahlis, Aurore Perrot et al. Nov 24, 2025 pp. LBA-6-LBA-6 10.1182/blood-2025-lba-6

Abstract Introduction: In RRMM, increasing rates of pt attrition and decreasing durability of responses with each line of therapy (LOT) nece...

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz et al. Nov 24, 2025 pp. LBA-3-LBA-3 10.1182/blood-2025-lba-3

Abstract Introduction: Pirtobrutinib is a highly selective, non-covalent (nc) Bruton tyrosine kinase inhibitor (BTKi) that has demonstrated...

A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The traction trial

Brett Houston, Daniel McIsaac, Rodney Breau et al. Nov 24, 2025 pp. LBA-5-LBA-5 10.1182/blood-2025-lba-5

Abstract BACKGROUND Whether a hospital policy of tranexamic acid administration for patients undergoing major noncardiac...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page